P909: RENAL RESPONSE OF POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT

P909: RENAL RESPONSE OF POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT

Bibliographic Details
Main Authors:	Y. Jian, L. Chang, M. Shi, Y. Sun, X. Chu, H. Xue, X. Shen, J. Ma, G. Jia, Y. Feng, Z. Xi, Y. Zhao, Y. Ma, J. Xiao, G. Ma, Q. Wang, W. Huang, L. Bao, Y. Dong, H. Zhou, C. Sun, G. Su, Y. Yan, Q. Saiyin, L. Su, S. Gao, W. Tian, X. Sun, H. Jing, D. Gao, W. Chen, J. Li, W. Gao
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846508.48688.f4

Similar Items

P909: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE CHEMOTHERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: POMACE PHASE II STUDY
by: Fen Saj, et al.
Published: (2023-08-01)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
by: Qian W, et al.
Published: (2020-01-01)

P976: BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE
by: Z. Yuping, et al.
Published: (2022-06-01)

P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPUS
by: W. Fu, et al.
Published: (2022-06-01)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
by: A. Oriol, et al.
Published: (2022-06-01)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
by: X. Jingyu, et al.
Published: (2022-06-01)

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
by: Li Y, et al.
Published: (2017-11-01)

Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
by: L. Wang, et al.
Published: (2015-06-01)

Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
by: L. Wang, et al.
Published: (2015-08-01)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
by: Aimaz Afrough, et al.
Published: (2023-10-01)

Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study
by: Chen R, et al.
Published: (2017-08-01)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
by: Chen W, et al.
Published: (2016-05-01)

Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
by: Fen Saj, et al.
Published: (2023-03-01)

P903: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED PATIENTS WITH MAYO 2004 STAGE 3 LIGHT-CHAIN AMYLOIDOSIS: A PROSPECTIVE PHASE 2 STUDY
by: Y.-J. Gao, et al.
Published: (2022-06-01)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
by: Z. Zhuang, et al.
Published: (2022-06-01)

POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS
by: M. Dimopoulos, et al.
Published: (2020-11-01)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
by: Cyrille Hulin, et al.
Published: (2021-10-01)

Predictive Value of Laboratory Indexes on Renal Involvement in Children with Henoch-Schönlein Purpura
by: Xi L, et al.
Published: (2021-11-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

P970: SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
by: Y. Wang, et al.
Published: (2022-06-01)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
by: Paul G. Richardson, et al.
Published: (2021-03-01)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
by: Despina Fotiou, et al.
Published: (2022-05-01)

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
by: P Sonneveld, et al.
Published: (2022-04-01)

Distribution of pomalidomide into semen of healthy male subjects after multiple doses
by: Li Y, et al.
Published: (2018-05-01)

Tomographic retrieval algorithm of OH concentration profiles using double spatial heterodyne spectrometers
by: Y. An, et al.
Published: (2020-12-01)

PB2011: CHIDAMIDE COMBINED WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (TC2D) AS AN ORAL QUADRUPLET REGIMEN FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: INITIAL RESULTS OF A PHASE IIA, MULTICENTER TRIAL
by: Y. Li, et al.
Published: (2022-06-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
by: Pieter Sonneveld, et al.
Published: (2022-10-01)

Synergistic Enhancement of Isoforskolin and Dexamethasone Against Sepsis and Acute Lung Injury Mouse Models
by: Fang Y, et al.
Published: (2023-12-01)

Elucidating the critical oligomeric steps in secondary organic aerosol and brown carbon formation
by: Y. Ji, et al.
Published: (2022-06-01)

P1120: THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA
by: A. Liu, et al.
Published: (2022-06-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Effects of dexamethasone, celecoxib, and methotrexate on the histology and metabolism of bone tissue in healthy Sprague Dawley rats
by: Liu YZ, et al.
Published: (2015-08-01)

The prediction of stone-free rate after flexible ureteroscopic lithotripsy for renal stones using artificial intelligence
by: Y-Q. Liu, et al.
Published: (2020-07-01)

Zeolitic Imidazolate Framework (ZIF-8) Decorated Iron Oxide Nanoparticles Loaded Doxorubicin Hydrochloride for Osteosarcoma Treatment - in vitro and in vivo Preclinical Studies
by: Wu W, et al.
Published: (2023-12-01)

The Potential of Visceral Adipose Tissue in Distinguishing Clear Cell Renal Cell Carcinoma from Renal Angiomyolipoma with Minimal Fat
by: Liu J, et al.
Published: (2021-11-01)

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
by: Dolph M, et al.
Published: (2021-06-01)

PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
by: C. Cerchione, et al.
Published: (2022-06-01)

Aquaporin 9 expression predicts outcomes and immune infiltrations in clear cell renal cell carcinoma
by: X. Tian, et al.
Published: (2020-07-01)